Search results for " hiv"

showing 10 items of 138 documents

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment.

2021

Due to medical advances over the past few decades, human immunodeficiency virus (HIV) infection, once a devastatingly mortal pandemic, has become a manageable chronic condition. However, available antiretroviral treatments (cART) cannot fully restore immune health and, consequently, a number of inflammation-associated and/or immunodeficiency complications have manifested themselves in treated HIV-infected patients. Among these chronic, non-AIDS (acquired immune deficiency syndrome)-related conditions, liver disease is one of the deadliest, proving to be fatal for 15–17% of these individuals. Aside from the presence of liver-related comorbidities, including metabolic disturbances and co-infe…

0301 basic medicineProgrammed cell deathChronic conditionantiretroviral drugs; apoptosis; hepatic cell death; HIV; liver; toxicityInflammationApoptosisHIV InfectionsReviewliverModels Biological03 medical and health sciencesLiver disease0302 clinical medicineImmune systemAntiretroviral Therapy Highly ActivemedicineHumans030212 general & internal medicinelcsh:QH301-705.5antiretroviral drugsImmunodeficiencybusiness.industryapoptosisHIVtoxicityGeneral Medicinemedicine.diseasehepatic cell death030104 developmental biologylcsh:Biology (General)LiverApoptosisImmunologyUnfolded protein responseHepatocytesmedicine.symptombusinessCells
researchProduct

HLA-E-Restricted CD8+ T Lymphocytes Efficiently Control Mycobacterium tuberculosis and HIV-1 Co-Infection

2020

We investigated the contribution of human leukocyte antigen A2 (HLA-A2) and HLA-E-restricted CD8+ T cells in patients with Mycobacterium tuberculosis and human immunodeficiency virus 1 (HIV-1) coinfection. HIV-1 downregulates HLA-A, -B, and -C molecules in infected cells, thus influencing recognition by HLA class I-restricted CD8+ T cells but not by HLA-E-restricted CD8+ T cells, owing to the inability of the virus to downmodulate their expression. Therefore, antigen-specific HLA-E-restricted CD8+ T cells could play a protective role in Mycobacterium tuberculosis and HIV-1 coinfection. HLA-E- and HLA-A2-restricted Mycobacterium tuberculosis-specific CD8+ T cells were tested in vitro for cyt…

0301 basic medicinePulmonary and Respiratory MedicineAdultMaleTetramersTuberculosisHLA-EClinical BiochemistryT lymphocytesDown-RegulationHIV InfectionsHuman leukocyte antigenCD8-Positive T-Lymphocytes+Lymphocyte ActivationMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineAntigenHLA-A2 AntigenmedicineCytotoxic T cellHumansTuberculosisLymphocyte CountMolecular BiologyAntigens BacterialbiologyCoinfectionHistocompatibility Antigens Class ICD8 T lymphocytes HLA-E Mycobacterium tuberculosis HIV tetramersCell BiologyCD8Mycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseVirology030104 developmental biology030228 respiratory systemCoinfectionHIV-1FemaleCD8Mycobacterium
researchProduct

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2019

AbstractWe reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustai…

0301 basic medicineSimeprevirLiver CirrhosisMalePyrrolidinesSofosbuvirSustained Virologic Responselcsh:MedicineSettore MED/05Gastroenterologychemistry.chemical_compound0302 clinical medicineLiver Function TestsINFECTIONMedicinePLUS SOFOSBUVIRlcsh:ScienceSulfonamidesMultidisciplinaryImidazolesValineHepatitis CMiddle AgedTreatment OutcomeItalySAFETYHCVSUSTAINED VIROLOGICAL RESPONSEDrug Therapy CombinationFemaleRIBAVIRINSettore BIO/19 - MICROBIOLOGIA GENERALECHRONIC HEPATITIS-Cmedicine.drugAdultmedicine.medical_specialtyDaclatasvirDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsArticle03 medical and health sciencesInternal medicineHumansAgedADVANCED LIVER-DISEASEbusiness.industryRibavirinVIRUS GENOTYPE 3lcsh:RHepatitis C ChronicHCV HIV Daclatasvirmedicine.diseaseIsoquinolinesEFFICACYRegimen030104 developmental biologychemistryAsunaprevirlcsh:QLiver functionCarbamatesSofosbuvirbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, >120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy

2016

Paola Di Carlo,1 Giuliana Guadagnino,1 Palmira Immordino,1 Giovanni Mazzola,2 Pietro Colletti,2 Ilenia Alongi,1 Lucia Adamoli,1 Francesco Vitale,1 Alessandra Casuccio1 1Department of Sciences for Health Promotion and Mother-Child Care “G D’Alessandro”, University of Palermo, 2Department of Medicinal Clinics and Emerging Diseases, “Paolo Giaccone” Polyclinic University Hospital, Palermo, Italy Aim: The authors examined a cohort of HIV-positive outpatients at the AIDS Center of Palermo University in Italy in order to identify factors related to the frequency of their visits to the outpatient facility for health care services.Methods: Two hundr…

0301 basic medicinemedicine.medical_specialtyMultivariate analysisSettore MED/17 - Malattie Infettivehard-to-reach groups030106 microbiologyHuman immunodeficiency virus (HIV)Medicine (miscellaneous)HIV Outpatient Servicemedicine.disease_causeSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineOutpatient facilityAmbulatory careAcquired immunodeficiency syndrome (AIDS)CD4+ T-cell countHealth careMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)Access to care; CD4+ T-cell count; Hard-to-reach groups; HIV infection; HIV outpatient service; Resource use; Social Sciences (miscellaneous); Medicine (miscellaneous); Health Policy; Pharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchaccess to carelcsh:R5-920business.industryHealth PolicyUnivariatemedicine.diseaseHIV infectionresource usePatient Preference and AdherenceEmergency medicineCohortbusinesslcsh:Medicine (General)Hard-to-reach groupSocial Sciences (miscellaneous)
researchProduct

Pathways of care for HIV infected children in Beira, Mozambique: pre-post intervention study to assess impact of task shifting

2018

Abstract Background In 2013, Mozambique implemented task-shifting (TS) from clinical officers to maternal and child nurses to improve care for HIV positive children < 5 years old. A retrospective, pre-post intervention study was designed to evaluate effectiveness of a new pathway of care in a sample of Beira District Local Health Facilities (LHFs), the primary, local, community healthcare services. Methods The study was conducted by accessing registries of At Risk Children Clinics (ARCCs) and HIV Health Services. Two time periods, pre- and post-intervention, were compared using a set of endpoints. Variables distribution was explored using descriptive statistics. T-student, Mann Whitney and …

0301 basic medicinemedicine.medical_specialtyReferralHIV InfectionsHIV infected childrenSettore MED/42 - Igiene Generale E ApplicataPost-intervention03 medical and health sciences0302 clinical medicineHIV exposed infants; HIV infected children; Human immunodeficiency virus; Paediatric HIV care and treatment; Pathways of care; Task-shiftingIntervention (counseling)EpidemiologyHealth caremedicineHumansHealth Workforce030212 general & internal medicineHuman immunodeficiency viruReferral and ConsultationMozambiqueRetrospective StudiesDescriptive statisticsbusiness.industryHuman immunodeficiency virusPublic healthlcsh:Public aspects of medicinePaediatric HIV care and treatmentPublic Health Environmental and Occupational HealthInfantHIV exposed infantlcsh:RA1-1270030112 virologyTask-shiftingHIV exposed infantsCD4 Lymphocyte CountChild PreschoolFamily medicineHealth Services ResearchBiostatisticsbusinessDelivery of Health CarePathways of careResearch ArticleBMC Public Health
researchProduct

Factors Associated With Weight Gain in People Treated With Dolutegravir.

2020

AbstractBackgroundAn unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.MethodsAdult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for …

0301 basic medicinemedicine.medical_specialtyWeight gain.HIV metabolic complications030106 microbiologyHIV metabolic complicationTDFEmtricitabineTenofovir alafenamidedolutegravir HIV metabolic complications TAF TDF weight gain.03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAbacavirInternal medicinemedicineMajor Article030212 general & internal medicinebusiness.industryWeight changeLamivudineweight gaindolutegravirInfectious DiseasesAcademicSubjects/MED00290OncologychemistryTAFRilpivirineDolutegravirmedicine.symptombusinessWeight gainmedicine.drugOpen forum infectious diseases
researchProduct

Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study

2021

Background. High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods. In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to e…

0301 basic medicinesub-Saharan AfricaMaleHIV AntibodieEpidemiologyHIV incidencesHIV Infectionsmortality rateHIV AntibodiesModelling studyHuman immunodeficiency virus prevalence0302 clinical medicineAfrica NorthernRA0421Seroepidemiologic StudiesMedicineNorthernHIV Infection030212 general & internal medicineYoung adult10. No inequalityuncertaintyMozambique11 Medical and Health SciencesHIV mortalityMortality rateIncidence (epidemiology)Incidence1. No povertyHiv incidencearticleMauritaniaHuman immunodeficiency virus infected patientArticlestrackingMiddle Agedhealth care planning3. Good healthPeer reviewLesothoAIDSInfectious DiseasesQR180A990 Medicine and Dentistry not elsewhere classifiedFemaleprenatal careanti human immunodeficiency virus agentseroepidemiologyHumanAdultAdolescentAnti-HIV AgentsImmunologyantiretroviral therapyUnit (housing)03 medical and health sciencesYoung AdultbloodHuman immunodeficiency virus infectionVirologySeroprevalenceHumanshumanDeveloping CountriesEstimationAcquired Immunodeficiency SyndromeSubnational mappingsbusiness.industrySeroepidemiologic StudieHIVAnti-HIV AgentPREVENTION030112 virologymortalitymonitoring3121 General medicine internal medicine and other clinical medicineHuman immunodeficiency virus antibodyAfricabusinessHIV incidence ; HIV mortality ; Subnational mapping ; Sub-Saharan Africa ; Local burden of disease ; Public healthDemography
researchProduct

Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives.

2002

Several 2,3-diaryl-1,3-thiazolidine-4-thione derivatives and 2,3-diaryl-1,3-thiazolidin-4-ones bearing a methyl group at C-5 position have been synthesized and tested as anti-HIV agents. The results of the in vitro tests showed that some of them proved to be effective inhibitors of HIV-1 replication.

23-Diaryl-13-thiazolidine-4-thioneAnti-HIV activity23-Diaryl-13-thiazolidin-4-oneStereochemistryAnti-HIV AgentsCell SurvivalPharmaceutical ScienceVirus ReplicationChemical synthesischemistry.chemical_compoundInhibitory Concentration 50Structure-Activity RelationshipThiadiazolesDrug DiscoveryThiadiazolesmedicineTumor Cells CulturedStructure–activity relationshipHumansAnti hiv activityReverse-transcriptase inhibitorGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaIn vitrochemistryNNRTIsLactamHIV-1EpimerMethyl groupmedicine.drugFarmaco (Societa chimica italiana : 1989)
researchProduct